NuCana Q2 loss narrows as clinical milestones remain on track - NCNA News | RalliesNuCana Q2 loss narrows as clinical milestones remain on track
N
NCNA• Management outlook
- NuCana anticipates cash resources will fund operations into 2029, supporting continued pipeline development
- Clinical progress includes completion of patient recruitment for the NUC-7738 Phase 2 expansion study in PD-1 inhibitor-resistant melanoma
Clinical milestones remain on track
- Company completed Phase 2 recruitment for NUC-7738; final data are expected later in 2026
- NuCana expects to announce final data from the Phase 2 NUC-7738 study later in 2026
- The company plans to seek FDA guidance on registrational strategy for NUC-7738 in melanoma
- It continues to assess additional indications and combination strategies for NUC-7738 and NUC-3373
Q2 loss narrows and cash runway extends
- UK cancer drug developer's Q2 net loss narrowed to £3.1 mln from £24.1 mln yr/yr
